Crinetics Pharmaceuticals Inc

CRNX

Healthcare|Biotechnology|USA

$83.58

-0.04 (-0.05%)

Tangible Book

$12.16

Clinical Trials (19)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT05192382 A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)	Acromegaly	P3	Active	111	RCT, Double-blind	Paltusotine, Placebo
NCT07087054 Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen	Carcinoid Syndrome, Carcinoid	P3	Recruiting	141	RCT, Double-blind	Paltusotine, Placebo
NCT07144163 A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia	Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia	P3	Recruiting	150	RCT, Double-blind	Atumelnant, Placebo
NCT07159841 A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)	Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia	P2P3	Recruiting	153	RCT, Double-blind	Atumelnant, Placebo
NCT04837040 A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly	Acromegaly	P3	Active	58	RCT, Double-blind	Paltusotine, Placebo
NCT06712823 An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia	Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia	P2	Recruiting	200	Open-label	atumelnant (CRN04894)
NCT05804669 A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome	Cushing Syndrome, Cushing Disease	P1P2	Recruiting	18	Open-label	atumelnant
NCT07129252 A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors	SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors	P1P2	Recruiting	150	Open-label	CRN09682
NCT04261712 A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)	Acromegaly	P2	Active	43	Open-label	Paltusotine
NCT07570082 Drug-Drug Interaction Study of Atumelnant in Healthy Participants	Healthy Volunteers	P1	Active	46	Open-label	Atumelnant, Carbamazepine, Midazolam, Digoxin, Metformin
NCT05907291 Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)	Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia	P2	Completed	38	Open-label	atumelnant (CRN04894)
NCT03789656 An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)	Acromegaly	P2	Completed	47	Open-label	Paltusotine
NCT03792555 A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)	Acromegaly	P2	Completed	13	RCT, Double-blind	Paltusotine, Placebo
NCT05361668 Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome	Carcinoid Syndrome, Carcinoid	P2	Completed	36	RCT, Open-label	Randomized: 40 mg Paltusotine, Randomized: 80 mg Paltusotine
NCT03936166 A Single and Multiple-Ascending Dose Study of CRN01941 in Healthy Adult Volunteers	Healthy Volunteers	P1	Completed	57	RCT, Double-blind	CRN01941 Oral Solution, CRN01941 Oral Capsule, Placebo Oral Solution, Placebo Oral Capsule
NCT04246749 Mass Balance and Pharmacokinetics of [14C]-CRN00808 in Healthy Volunteers	Healthy Volunteers	P1	Completed	11	Open-label	[14C]-CRN00808, CRN00808
NCT03276858 Single and Multiple-Ascending Dose Study of CRN00808 in Healthy Volunteers	Healthy Volunteers	P1	Completed	99	RCT, Double-blind	CRN00808, Placebo Oral Solution, Midazolam oral solution, Placebo oral capsule
NCT07221084 A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants	Healthy Volunteers	P1	Completed	21	RCT, Double-blind	Atumelnant, Placebo
NCT06048887 Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers	Healthy Volunteers	P1	Completed	88	RCT, Double-blind	CRN04894 Oral Solution, Placebo Oral Solution